NXTC NextCure, Inc. - Common Stock
$6.92
价格 · 八月 19, 2026
截至...的财报数据 八月 6, 2026
52周区间
$2–$16
38% of range
分析师评级
BUY
8 analysts
目标价
$20
+189% upside
P/E (TTM)
-0.4
ROE
-172.9%
净利润率
—
NXTC 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$6.92
市值
$25M
P/E (TTM)
-0.4
每股收益 (TTM)
$-19.65
营收 (TTM)
—
股息收益率
—
ROE
-172.9%
负债/权益
—
52周区间
$2 – $16
NXTC 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
2019-12-31
→
2020-12-31
EPS
$-19.65
2020-12-31
→
2025-12-31
自由现金流
—
2019-12-31
→
2024-12-31
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
NXTC
同行中位数
P/E (TTM)
-0.4
0.8
P/S (TTM) (市销率 (TTM))
0.9
6.2
P/B (市净率)
0.7
3.0
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
NXTC
同行中位数
ROA
-85.2%
-118.6%
ROE
-172.9%
-139.5%
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
NXTC
同行中位数
Current Ratio (流动比率)
4.1
2.1
Quick Ratio (速动比率)
2.5
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
NXTC
同行中位数
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
NXTC
同行中位数
NXTC 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
8 位分析师
- 强烈买入 2 25.0%
- 买入 5 62.5%
- 持有 1 12.5%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
3 位分析师 · 2026-08-15
中位数
$20.00
← 低于所有目标
$6.92
最低
$15.00
最高
$25.00
中位数目标
$20.00
+188.9%
平均目标
$20.00
+188.9%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.74%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-2.80 | $-1.97 | -0.83% |
| 2026年3月31日 | $-1.87 | $-2.15 | 0.28% |
| 2025年12月31日 | $-0.81 | $-2.46 | 1.7% |
| 2025年9月30日 | $-3.22 | $-4.06 | 0.84% |
| 2025年6月30日 | $-11.29 | $-4.71 | -6.6% |
| 2025年3月31日 | $-4.68 | $-4.90 | 0.22% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| NXTC | $50M | -0.7 | — | — | -172.9% | — |
| ESLA | — | -4.5 | — | — | — | — |
| LITS | $16M | -1.0 | 33.8% | — | -81.7% | — |
| GRML | — | — | — | — | -104.9% | — |
| QNCX | $187M | -2.0 | — | — | 700.5% | — |
| LTRN | — | -1.9 | — | — | — | — |
| BYSI | — | — | — | — | 3.1% | — |
| DYAI | — | -4.1 | -11.6% | — | — | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | $22M | $6M | |
| R&D Expense | $45M | $41M | $48M | $54M | $50M | $47M | $34M | |
| SG&A Expense | $13M | $16M | $20M | $22M | $21M | $17M | $10M | |
| Operating Expenses | $58M | $60M | $68M | $76M | $71M | $64M | $44M | |
| Operating Income | $-58M | $-60M | $-68M | $-76M | $-71M | $-41M | $-37M | |
| Interest Expense | · | · | · | · | · | $183.0K | $209.0K | |
| Other Non-op | $2M | $4M | $5M | $1M | $1M | $5M | $4M | |
| Income Tax | $0 | · | · | · | · | · | · | |
| Net Income | $-56M | $-56M | $-63M | $-75M | $-69M | $-37M | $-34M | |
| EPS (Basic) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | · | |
| EPS (Diluted) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | · | |
| Shares (Basic) | 2,842,448 | 2,330,386 | 27,836,584 | 27,744,209 | 27,615,977 | 27,532,177 | · | |
| Shares (Diluted) | 2,842,448 | 2,330,386 | 27,836,584 | 27,744,209 | 27,615,977 | 27,532,177 | · | |
| EBITDA | $-55M | $-57M | $-64M | $-72M | $-66M | · | $-35M |
资产负债表 23
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26M | $28M | $13M | $27M | $12M | $33M | $34M | |
| Prepaid Expense | $2M | $3M | $4M | $4M | $8M | $3M | $4M | |
| Current Assets | $44M | $72M | $113M | $164M | $228M | $288M | $340M | |
| PP&E (Net) | $3M | $5M | $9M | $12M | $14M | $16M | $12M | |
| PP&E (Gross) | $29M | $29M | $29M | $29M | $27M | $24M | $17M | |
| Accum. Depreciation | $25M | $23M | $20M | $17M | $13M | $9M | $5M | |
| Other Non-current Assets | $546.0K | $332.0K | $2M | $3M | $577.0K | $3M | $4M | |
| Total Assets | $50M | $81M | $128M | $184M | $242M | $307M | $356M | |
| Accounts Payable | $2M | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | · | · | · | · | $4M | $5M | $5M | |
| Current Liabilities | $11M | $10M | $7M | $9M | $7M | $10M | $15M | |
| Capital Leases | $4M | $5M | $6M | $7M | · | · | · | |
| Other Non-current Liabilities | $526.0K | $661.0K | $785.0K | $899.0K | $2M | · | · | |
| Total Liabilities | $15M | $15M | $14M | $17M | $9M | $13M | $35M | |
| Long-term Debt | · | · | · | $0 | $0 | $4M | $5M | |
| Total Debt | · | · | · | · | · | · | $5M | |
| Common Stock | $4.0K | $2.0K | $28.0K | $28.0K | $28.0K | $28.0K | $27.0K | |
| Paid-in Capital | $471M | $446M | $439M | $431M | $421M | $411M | $403M | |
| Retained Earnings | $-436M | $-380M | $-324M | $-262M | $-187M | $-118M | $-81M | |
| AOCI | $21.0K | $4.0K | $-222.0K | $-1M | $-663.0K | $779.0K | $-38.0K | |
| Stockholders' Equity | $35M | $65M | $114M | $168M | $233M | $294M | $321M | |
| Liabilities + Equity | $50M | $81M | $128M | $184M | $242M | $307M | $356M | |
| Shares Outstanding | 3,505,621 | 2,333,896 | 2,325,259 | 27,774,536 | 27,680,997 | 27,568,802 | 27,499,260 |
现金流 11
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $3M | $4M | $4M | $4M | $3M | $3M | |
| Stock-based Comp | $3M | $6M | $8M | $10M | $10M | $8M | $2M | |
| Other Non-cash | $1M | $6M | $-2M | $7M | $-2M | · | $-6M | |
| Operating Cash Flow | $-50M | $-41M | $-53M | $-54M | $-57M | $-45M | $-36M | |
| CapEx | · | $474.0K | $820.0K | $2M | $2M | $7M | $3M | |
| Investing Cash Flow | $26M | $55M | $39M | $68M | $37M | $44M | $-304M | |
| Stock Issued | · | $39.0K | $5.0K | · | · | $112.0K | $119.0K | |
| Net Stock Activity | · | $39.0K | · | · | · | · | $119.0K | |
| Financing Cash Flow | $22M | $144.0K | $154.0K | $200.0K | $-3M | $-1M | $243M | |
| Net Change in Cash | $-2M | $15M | $-14M | $14M | $-24M | $-3M | $-97M | |
| Free Cash Flow | · | $-41M | $-54M | $-56M | $-60M | · | $-39M |
盈利能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | -590.5% | |
| Net Margin | · | · | · | · | · | · | -531.5% | |
| EBITDA Margin | · | · | · | · | · | · | -548.0% | |
| ROA | -85.2% | -53.3% | -40.2% | -35.0% | -25.3% | · | -13.4% | |
| ROE | -172.9% | -78.9% | -52.1% | -42.8% | -28.8% | · | -13.7% |
流动性与偿付能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 7.5 | 16.4 | 18.0 | 34.5 | · | 22.6 | |
| Quick Ratio | 2.5 | 2.9 | 1.9 | 2.9 | 1.9 | · | 2.3 | |
| Debt / Equity | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | -179.3 |
效率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | 0.0 |
估值 (TTM) 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $27M | $27M | $27M | $27M | $22M | $6M | |
| Net Income TTM | $-56M | $-56M | $-63M | $-75M | $-69M | $-37M | $-34M | |
| Market Cap | $50M | $259M | $382M | $470M | $1.99B | · | $18.59B | |
| Enterprise Value | · | · | · | · | · | · | $18.56B | |
| P/E | -0.7 | -0.4 | -6.1 | -6.3 | -28.7 | -98.3 | · | |
| P/S | 1.9 | 9.7 | 14.3 | 17.6 | 74.6 | · | 2928.7 | |
| P/B | 1.4 | 4.0 | 3.3 | 2.8 | 8.5 | · | 57.8 | |
| P / Tangible Book | 1.4 | 4.0 | 3.3 | 2.8 | 8.5 | 12.3 | · | |
| P / Cash Flow | -1.0 | -6.4 | -7.2 | -8.7 | -34.8 | · | -521.8 | |
| P / FCF | · | -6.3 | -7.1 | -8.4 | -33.4 | · | -476.7 | |
| EV / EBITDA | · | · | · | · | · | · | -533.6 | |
| EV / FCF | · | · | · | · | · | · | -476.0 | |
| EV / Revenue | · | · | · | · | · | · | 2924.1 | |
| Earnings Yield | -138.5% | -258.1% | -16.4% | -15.9% | -3.5% | -1.0% | · |
损益表 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $7M | $7M | $7M | $6M | $24M | $8M | $9M | $9M | $12M | $11M | $12M | $11M | $13M | $12M | $13M | $14M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $6M | $5M | $5M | $6M | |
| Operating Expenses | $15M | $10M | $10M | $9M | $27M | $12M | $12M | $12M | $16M | $18M | $16M | $16M | $19M | $17M | $18M | $19M | |
| Operating Income | $-15M | $-10M | $-10M | $-9M | $-27M | $-12M | $-12M | $-12M | $-16M | $-18M | $-16M | $-16M | $-19M | $-17M | $-18M | $-19M | |
| Other Non-op | $202.0K | $309.0K | $321.0K | $321.0K | $484.0K | $646.0K | $852.0K | $955.0K | $1M | $1M | $1M | $1M | $1M | $975.0K | $471.0K | $328.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Net Income | $-15M | $-10M | $-9M | $-9M | $-27M | $-11M | $-12M | $-12M | $-15M | $-17M | $-14M | $-14M | $-18M | $-16M | $-17M | $-19M | |
| EPS (Basic) | $-2.80 | $-1.87 | $-4.75 | $-3.22 | $-11.29 | $-4.70 | $-11.71 | $-4.95 | $-6.61 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.58 | $-0.62 | $-0.68 | |
| EPS (Diluted) | $-2.80 | $-1.87 | $-4.75 | $-3.22 | $-11.29 | $-4.70 | $-11.71 | $-4.95 | $-6.61 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.58 | $-0.62 | $-0.68 | |
| Shares (Basic) | 5,309,724 | 5,239,236 | -30,215,081 | 2,676,116 | 2,374,729 | 2,333,890 | -30,235,036 | 2,331,320 | 2,331,062 | 27,903,040 | -55,606,661 | 27,839,968 | 27,828,741 | 27,774,536 | -55,458,165 | 27,748,844 | |
| Shares (Diluted) | 5,309,724 | 5,239,236 | -30,215,081 | 2,676,116 | 2,374,729 | 2,333,890 | -30,235,036 | 2,331,320 | 2,331,062 | 27,903,040 | -55,606,661 | 27,839,968 | 27,828,741 | 27,774,536 | -55,458,165 | 27,748,844 | |
| EBITDA | $-15M | $-10M | · | $-9M | $-27M | $-12M | · | $-12M | $-16M | $-18M | · | $-16M | $-19M | $-17M | · | $-19M |
资产负债表 21
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $15M | $26M | $7M | $5M | $22M | $28M | $28M | $21M | $18M | $13M | $20M | $22M | $30M | $27M | $31M | |
| Prepaid Expense | $2M | $2M | $2M | $4M | $5M | $3M | $3M | $3M | $4M | $7M | $4M | $4M | $5M | $3M | $4M | $6M | |
| Current Assets | $22M | $32M | $44M | $33M | $40M | $59M | $72M | $79M | $90M | $103M | $113M | $123M | $135M | $149M | $164M | $175M | |
| PP&E (Net) | $283.0K | $3M | $3M | $4M | $4M | $5M | $5M | $6M | $7M | $7M | $9M | $10M | $11M | $11M | $12M | $12M | |
| PP&E (Gross) | · | · | $29M | · | · | · | $29M | · | · | · | $29M | · | · | · | $29M | · | |
| Accum. Depreciation | · | · | $25M | · | · | · | $23M | · | · | · | $20M | · | · | · | $17M | · | |
| Other Non-current Assets | $82.0K | $847.0K | $546.0K | $550.0K | $555.0K | $328.0K | $332.0K | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | |
| Total Assets | $23M | $38M | $50M | $40M | $48M | $67M | $81M | $90M | $103M | $115M | $128M | $140M | $153M | $168M | $184M | $190M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $3M | $3M | $5M | $4M | $5M | $4M | $2M | $3M | $3M | $2M | $4M | $2M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Current Liabilities | $6M | $7M | $11M | $11M | $11M | $6M | $10M | $9M | $11M | $10M | $7M | $7M | $8M | $6M | $9M | $6M | |
| Capital Leases | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $7M | · | |
| Other Non-current Liabilities | $455.0K | $491.0K | $526.0K | $561.0K | $596.0K | $629.0K | $661.0K | $693.0K | $725.0K | $755.0K | $785.0K | $815.0K | $843.0K | $872.0K | $899.0K | · | |
| Total Liabilities | $10M | $11M | $15M | $16M | $16M | $11M | $15M | $15M | $17M | $16M | $14M | $13M | $15M | $14M | $17M | $8M | |
| Common Stock | $4.0K | $4.0K | $4.0K | $3.0K | $2.0K | $28.0K | $2.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | |
| Paid-in Capital | $473M | $472M | $471M | $450M | $448M | $447M | $446M | $444M | $442M | $441M | $439M | $437M | $435M | $433M | $431M | $428M | |
| Retained Earnings | $-461M | $-446M | $-436M | $-427M | $-418M | $-391M | $-380M | $-369M | $-357M | $-342M | $-324M | $-310M | $-296M | $-278M | $-262M | $-244M | |
| AOCI | $-3.0K | $-2.0K | $21.0K | $17.0K | $-7.0K | · | $4.0K | $76.0K | $-86.0K | $-182.0K | $-222.0K | $-603.0K | $-925.0K | $-803.0K | $-1M | $-2M | |
| Stockholders' Equity | $12M | $27M | $35M | $24M | $30M | $56M | $65M | $76M | $85M | $99M | $114M | $126M | $138M | $154M | $168M | $182M | |
| Liabilities + Equity | $23M | $38M | $50M | $40M | $48M | $67M | $81M | $90M | $103M | $115M | $128M | $140M | $153M | $168M | $184M | $190M | |
| Shares Outstanding | 4,068,951 | 3,607,555 | 3,505,621 | 2,676,110 | 2,337,516 | 28,006,684 | 2,333,896 | 27,975,840 | 27,975,840 | 27,903,627 | 27,903,027 | 27,839,968 | 27,839,968 | 27,774,536 | 27,774,536 | 27,748,844 |
现金流 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $304.0K | $344.0K | $435.0K | $600.0K | $588.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-10M | $-13M | $-8M | $-6M | $-23M | $-13M | $-7M | $-11M | $-10M | $-13M | $-11M | $-13M | $-15M | $-15M | $-9M | $-15M | |
| CapEx | · | · | · | · | · | · | $-34.0K | $170.0K | $301.0K | $37.0K | $13.0K | $279.0K | $280.0K | $248.0K | $865.0K | $532.0K | |
| Investing Cash Flow | $10M | $1M | $6M | $9M | $4M | $7M | $7M | $18M | $12M | $18M | $4M | $10M | $7M | $18M | $4M | $18M | |
| Stock Issued | $0 | $1M | · | · | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $1M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $22.0K | $1M | $20M | $0 | · | · | $37.0K | $0 | $106.0K | $1.0K | $71.0K | $0 | · | · | $61.0K | $0 | |
| Net Change in Cash | $93.0K | $-11M | $19M | $2M | $-17M | $-6M | $26.0K | $7M | $2M | $5M | $-6M | $-2M | $-8M | $3M | $-4M | $3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-13M | · | · | · | $-15M | · | · |
盈利能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -42.4% | -18.6% | · | -13.3% | -35.7% | -12.0% | · | -10.0% | -12.0% | -12.1% | · | -8.7% | -9.9% | -8.2% | · | -8.5% | |
| ROE | -71.3% | -23.7% | · | -17.4% | -46.6% | -14.2% | · | -11.4% | -13.8% | -13.5% | · | -9.3% | -10.6% | -8.7% | · | -8.8% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.6 | · | 3.0 | 3.7 | 10.3 | · | 9.1 | 8.3 | 10.7 | · | 18.7 | 17.3 | 23.8 | · | 29.8 | |
| Quick Ratio | 2.4 | 2.2 | · | 0.7 | 0.5 | 3.8 | · | 3.2 | 1.9 | 1.9 | · | 3.0 | 2.8 | 4.8 | · | 5.3 |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $27M | · | $27M | $27M | $27M | · | $27M | $27M | $27M | · | $27M | $27M | $27M | · | $27M | |
| Net Income TTM | $-60M | $-56M | · | $-58M | $-65M | $-55M | · | $-58M | $-65M | $-65M | · | $-67M | $-71M | $-74M | · | $-75M | |
| Market Cap | $7M | $39M | · | $16M | $13M | $161M | · | $460M | $534M | $747M | · | $431M | $601M | $493M | · | $916M | |
| P/E | -0.1 | -0.5 | · | -0.3 | -0.2 | -0.5 | · | -1.3 | -2.3 | -11.4 | · | -6.4 | -8.5 | -6.7 | · | -12.1 | |
| P/S | 0.2 | 1.4 | · | 0.6 | 0.5 | 6.0 | · | 17.2 | 20.0 | 27.9 | · | 16.1 | 22.5 | 18.5 | · | 34.3 | |
| P/B | 0.5 | 1.4 | · | 0.7 | 0.4 | 2.9 | · | 6.1 | 6.2 | 7.5 | · | 3.4 | 4.3 | 3.2 | · | 5.0 | |
| P / Tangible Book | 0.5 | 1.4 | · | 0.7 | 0.4 | 2.9 | · | 6.1 | 6.2 | 7.5 | · | 3.4 | 4.3 | 3.2 | · | 5.0 | |
| P / Cash Flow | · | -2.9 | · | · | · | -12.4 | · | · | · | -59.2 | · | · | · | -33.4 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -59.1 | · | · | · | -32.8 | · | · | |
| Earnings Yield | -1198.8% | -197.4% | · | -338.7% | -421.0% | -218.1% | · | -77.1% | -43.9% | -8.7% | · | -15.6% | -11.8% | -14.9% | · | -8.2% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 净收入 | $-56M | $-56M | $-63M | $-75M | $-69M |
| 稀释后每股收益 (EPS) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 4.1 | 7.5 | 16.4 | 18.0 | 34.5 |
| 速动比率 | 2.5 | 2.9 | 1.9 | 2.9 | 1.9 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | — | $-41M | $-54M | $-56M | $-60M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 31 家申报者 · $2.7M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 11 (+4 与上一季度对比) | 7 (+3 与上一季度对比) | 5 (+2 与上一季度对比) | 7 (+3 与上一季度对比) | -363K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 23 位内幕人士 · 11 位高管 · 13 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Michael Richman | President & CEO | 2026年1月30日 A | — | 0 | 0 | $0 |
| Steven P. Cobourn | Chief Financial Officer | 2026年1月30日 A | — | 0 | 0 | $0 |
| Timothy Mayer | Chief Operating Officer | 2026年1月30日 A | — | 0 | 0 | $0 |
| Udayan Guha | Chief Medical Officer | 2026年1月30日 A | — | 0 | 0 | $0 |
| Kevin G. Shaw | Sr VP, General Counsel | 2026年1月30日 A | — | 0 | 0 | $0 |
| Sourav Kundu | Sr VP, Dev. & Mfg. | 2026年1月30日 A | — | 0 | 0 | $0 |
| Sol Langermann | Chief Scientific Officer | 2025年1月31日 A | — | 0 | 0 | $0 |
| Han Myint | Chief Medical Officer | 2024年3月29日 A | — | 0 | 0 | $0 |
| Linda Liu | SVP, Research | 2022年1月31日 A | 55234 | 0 | 0 | $0 |
| Kevin N. Heller | Chief Medical Officer | 2020年7月14日 M | 49011 | 0 | 0 | $0 |
| James B. Bingham | Chief Development Officer | 2020年2月28日 A | — | 0 | 0 | $0 |
| Anne Elizabeth Borgman | 董事 | 2026年6月18日 A | — | 0 | 0 | $0 |
| Ellen Feigal | 董事 | 2026年6月18日 A | — | 0 | 0 | $0 |
| John G Houston | 董事 | 2026年6月18日 A | — | 0 | 0 | $0 |
| Stephen W Webster | 董事 | 2026年6月18日 A | — | 0 | 0 | $0 |
| Elaine V Jones | 董事 | 2026年6月18日 A | — | 0 | 0 | $0 |
| KABAKOFF DAVID S | 董事 | 2026年6月18日 A | — | 0 | 0 | $0 |
| Garry A Nicholson | 董事 | 2023年6月22日 A | — | 0 | 0 | $0 |
| Chau Quang Khuong | 董事 | 2023年6月22日 A | 2711013 | 0 | 0 | $0 |
| Judith Li | 董事 | 2020年6月11日 A | — | 0 | 0 | $0 |
| Stella Xu | 董事 | 2020年6月11日 A | 1103570 | 0 | 0 | $0 |
| Briggs Morrison | 董事 | 2020年6月11日 A | — | 0 | 0 | $0 |
| Timothy M Shannon | 董事 | 2019年6月13日 A | 2254442 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Sofinnova Venture Partners IX, L.P. ("SVP IX"), Sofinnova Management IX, L.L.C. ("SM IX"), Dr. James I. Healy ("Healy") | 2026年3月5日 | 7.10% | 修订 | 被动投资 | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC ×3 申报 | 2024年3月8日 | — | 初始申报 | — | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×2 申报 | 2019年11月22日 | — | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 5 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。